Cabenuva
Active Ingredient(s): Cabotegravir + RilpivirineFDA Approved: * January 21, 2021
Pharm Company: * VIIV HLTHCARE
Category: HIV / AIDS
Cabotegravir/rilpivirine, sold under the brand name Cabenuva, is a co-packaged antiretroviral medication for the treatment of HIV/AIDS.[2][3][4][5] It contains cabotegravir and rilpivirine in a package with two separate injection vials.[2][3][5] The most common adverse reactions include injection site reactions, fever or feeling hot (pyrexia), fatigue, headache, musculoskeletal pain... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.